A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy
- 1 December 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (23), 6984-6992
- https://doi.org/10.1158/1078-0432.ccr-07-1409
Abstract
Purpose: Our goal was to examine a panel of 11 biochemical variables, measured in cytosolic extracts of ovarian tissues (normal, benign, and malignant) by quantitative ELISAs for their ability to diagnose, prognose, and predict response to chemotherapy of ovarian cancer patients. Experimental Design: Eleven proteins were measured (9 kallikreins, B7-H4, and CA125) in cytosolic extracts of 259 ovarian tumor tissues, 50 tissues from benign conditions, 35 normal tissues, and 44 tissues from nonovarian tumors that metastasized to the ovary. Odds ratios and hazard ratios and their 95% confidence interval were calculated. Time-dependent receiver operating characteristic curves for censored survival data were used to evaluate the performance of the biomarkers. Resampling was used to validate the performance. Results: Most biomarkers effectively separated cancer from noncancer groups. A composite marker provided an area under the curve of 0.97 (95% confidence interval, 0.95-0.99) for discriminating normal and cancer groups. Univariately, hK5 and hK6 were positively associated with progression. After adjusting for clinical variables in multivariate analysis, both hK10 and hK11 significantly predicted time to progression. Increasing levels of hK13 were associated with chemotherapy response, and the predictive power of hK13 to chemotherapy response was improved by a panel of five biomarkers. Conclusions: The evidence shows that a group of kallikreins and multiparametric combinations with other biomarkers and clinical variables can significantly assist with ovarian cancer classification, prognosis, and response to platinum-based chemotherapy. In particular, we developed a multiparametric strategy for predicting ovarian cancer response to chemotherapy, comprising several biomarkers and clinical features.Keywords
Other Versions
This publication has 43 references indexed in Scilit:
- Ovarian cancer specific kallikrein profile in effusionsGynecologic Oncology, 2007
- Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer CytosolsClinical Chemistry, 2006
- Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targetsInternational Journal of Gynecologic Cancer, 2005
- Kallikrein 4 Expression Is Up-Regulated in Epithelial Ovarian Carcinoma Cells in EffusionsAmerican Journal of Clinical Pathology, 2005
- Downregulation of Human Kallikrein 10 (KLK10/NES1) by CpG Island Hypermethylation in Breast, Ovarian and Prostate CancersTumor Biology, 2005
- Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian CancerJournal of Clinical Oncology, 2004
- Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic MarkerJournal of Clinical Oncology, 2004
- In silico Analysis of the Human Kallikrein Gene 6Tumor Biology, 2004
- Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinomaInternational Journal of Cancer, 2003
- The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cellsCancer, 1999